Sponsored Links
| KYTHERA And Intendis Announce Initiation Of European Phase III Clinical Development Program To Evaluate ATX-101 For Reduction Of Submental Fat |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") and Intendis, Bayer HealthCare's dermatology business, announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat)... Read more: Clinical Trials / Drug Trials News From Medical News Today
|